Eligibility criteria
Condition
Ankylosing Spondylitis
Sex
Females and Males
Age
18 + years
Inclusion criteria
Show details
- Diagnosis of ankylosing spondylitis
Exclusion criteria
Show details
- Contraindications according SmPC
You are here
Study Evaluating Enbrel (Etanercept) in Patients With Ankylosing Spondylitis
NCT00227227
Last updated on December 5, 2019
About this Study
The purpose of this study is to investigate the incidence of adverse events for patients with AS treated with Enbrel in usual care settings.
NCT00227227
Pfizer
Completed
Study Evaluating Enbrel (Etanercept) in Patients With Ankylosing Spondylitis
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
Based on your search, you may also be interested in
Crohn Desease, Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis
NCT02925338
All Genders
6+
Years
Multiple Sites
Ankylosing Spondylitis
NCT02202850
All Genders
18+
Years
Multiple Sites
| Descriptive Information | |||||||
|---|---|---|---|---|---|---|---|
| Brief Title | Study Evaluating Enbrel (Etanercept) in Patients With Ankylosing Spondylitis | ||||||
| Official Title | Observational Study With Enbrel (Etanercept) in Patients With Ankylosing Spondylitis | ||||||
| Brief Summary | The purpose of this study is to investigate the incidence of adverse events for patients with AS treated with Enbrel in usual care settings. | ||||||
| Detailed Description | Not Provided | ||||||
| Study Type | Observational | ||||||
| Study Design | Time Perspective: Prospective | ||||||
| Target Follow-Up Duration | Not Provided | ||||||
| Biospecimen | Not Provided | ||||||
| Sampling Method | Not Provided | ||||||
| Study Population | Not Provided | ||||||
| Condition | Ankylosing Spondylitis | ||||||
| Intervention | Not Provided | ||||||
| Study Groups/Cohorts | Not Provided | ||||||
| Publications * | Not Provided | ||||||
| * Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | |||||||
| Recruitment Information | |||||||
| Recruitment Status | Completed | ||||||
| Estimated Enrollment | 750 | ||||||
| Original Enrollment | Same as current | ||||||
| Actual Study Completion Date | June 2007 | ||||||
| Primary Completion Date | Not Provided | ||||||
| Eligibility Criteria | Inclusion Criteria:
Exclusion Criteria:
| ||||||
| Sex/Gender |
| ||||||
| Ages | 18 Years and older (Adult, Older Adult) | ||||||
| Accepts Healthy Volunteers | No | ||||||
| Contacts | Contact information is only displayed when the study is recruiting subjects | ||||||
| Listed Location Countries | Germany | ||||||
| Removed Location Countries | |||||||
| Administrative Information | |||||||
| NCT Number | NCT00227227 | ||||||
| Other Study ID Numbers | 101540 | ||||||
| Has Data Monitoring Committee | Not Provided | ||||||
| U.S. FDA-regulated Product | Not Provided | ||||||
| IPD Sharing Statement | Not Provided | ||||||
| Responsible Party | Not Provided | ||||||
| Study Sponsor | Wyeth is now a wholly owned subsidiary of Pfizer | ||||||
| Collaborators | Not Provided | ||||||
| Investigators |
| ||||||
| PRS Account | Wyeth is now a wholly owned subsidiary of Pfizer | ||||||
| Verification Date | December 2007 | ||||||
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
BY PHONE
Pfizer Clinical Trials Contact Center
1-800-718-1021